- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05009771
Postoperative Schmerztherapie beim Kaiserschnitt
Postoperative Schmerzbehandlung beim Kaiserschnitt: eine prospektive Kohortenbeobachtungsstudie
Caesarean section is one of the most frequent surgeries causing severe postoperative pain. Poor management of acute pain can contribute to postoperative complications, late recovery and the development of chronic pain. Moreover, it had been demonstrated that the intensity of postpartum pain is associated with depression. It is imperative to find out appropriate methods of postpartum pain alleviation. Currently, a lot of analgesic drugs and methods have been developed and used in clinical practice, such as patient-controlled analgesia, extended-release analgesics and multimodal analgesia. This prospective cohort study is aimed to investigate the outcome of each postoperative analgesic method used in caesarean section.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a prospective, observational, cohort study. Patients undergoing elective caesarean section will be invited to the study. The written informed consent will be obtained prior to participation. After getting the written informed consent, data will be collected from medical records, questionnaires, patient diaries, visit records and telephone visit records. Through telephone visits, postpartum depression scale and postpartum chronic pain will be evaluated six weeks and three months after delivery. Demographic data, consumption of analgesics, analgesic methods, intensity of postoperative pain, complications, recovery time, score of depression scale will all be summarized. Numerical variables will be present with mean and standard deviation and categorical variables will be present with number and percentage.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
New Taipei City, Taiwan, 251
- MacKay Memorial Hospital Tamsui Branch
-
Taipei, Taiwan, 104
- MacKay Memorial Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Pregnant woman scheduled to have caesarean section within 30 days.
Beschreibung
Inclusion Criteria:
- Aged 20 to 40.
- Planing to undergo caesarean section with spinal anesthesia.
- Scheduled to undergo cesarean section between 37 and 40 weeks of gestation.
- American Society of Anesthesiology Physical Class 1-2.
- Planing to alleviate postoperative pain with intravenous patient-controlled analgesia or administration of NALDEBAIN.
Exclusion Criteria:
- Not willing to provide informed consent.
- Unable to receive opioids or NSAIDs due to contraindication.
- Long-term use of opioids or drug abuse.
- Suffering from chronic pain disease.
- Having medical history of mental illnesses.
- Diagnosed with Pre-eclampsia or eclampsia.
- Diagnosed with gestational diabetes.
- Unsuitable for participation judged by investigator.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
IV-PCA + NALDEBAIN group
Patients treated with the combination of IV-PCA and intramuscular injection of dinalbuphine sebacate will be allocated to IV-PCA + NALDEBAIN group. |
At the two trial sites, IV-PCA is commonly used with morphine. The device is installed after delivery and removed within 3 days.
Andere Namen:
Dinalbuphine sebacate is a prodrug of nalbuphine. With oil-based formulation, the active ingredient releases slowly and the effect lasts longer than nalbuphine. After delivery, a single 150 mg dose of dinalbuphine sebacate is administered intramuscularly.
Andere Namen:
|
|
IV-PCA group
Patients receiving intravenous patient-controlled analgesia (IV-PCA) will be allocated to IV-PCA group. |
At the two trial sites, IV-PCA is commonly used with morphine. The device is installed after delivery and removed within 3 days.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Postpartum pain intensity
Zeitfenster: Within 5 days after delivery
|
Pain intensity is assessed by numerical rating scale (NRS) at least twice daily during hospital stay after delivery. NRS is a 11-point scale which labeled from zero (no pain) to ten (worst pain). The area under the curve of NRS are calculated. |
Within 5 days after delivery
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Consumption of analgesics
Zeitfenster: Within 5 days after delivery
|
The mean total consumption of analgesics during the hospital stay after delivery. |
Within 5 days after delivery
|
|
Incidence of complications
Zeitfenster: Up to 5 days after delivery
|
the incidence of postoperative complication occurring during hospital stay after delivery, especially the ones related to analgesics. |
Up to 5 days after delivery
|
|
Ambulation
Zeitfenster: Up to 5 days after delivery
|
The mean length of time between delivery and the first ambulation. |
Up to 5 days after delivery
|
|
Breastfeeding
Zeitfenster: Up to 5 days after delivery
|
The percentage of participants able to breastfeed during hospital stay and the mean length of time between delivery and the first breastfeeding. |
Up to 5 days after delivery
|
|
Gastrointestinal function recovery
Zeitfenster: Up to 5 days after delivery
|
The mean length of time between delivery and first soft diet. |
Up to 5 days after delivery
|
|
Postnatal Depression assessment
Zeitfenster: At baseline, 6 weeks and 3 months after delivery
|
Edinburgh Postnatal Depression questionnaire is used to assess patients' postpartum depression. Participants are asked to fill in the questionnaire at baseline (within 30 days prior to delivery), 6 weeks and 3 months after delivery. |
At baseline, 6 weeks and 3 months after delivery
|
|
Satisfaction assessed by a four-point scale
Zeitfenster: 6 weeks after delivery
|
Participants are asked to assess the satisfaction toward rate of recovery progress and pain management through 6 questions six weeks after delivery. Each question contain 4 choices: very satisfied, satisfied, dissatisfied and very dissatisfied. |
6 weeks after delivery
|
|
Chronic pain intensity
Zeitfenster: 6 weeks and 3 months after delivery
|
Chronic pain intensity is assessed by NRS 6 weeks and 3 months after delivery. NRS is a 11-point scale which labeled from zero (no pain) to ten (worst pain). |
6 weeks and 3 months after delivery
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Chi-Hsu Wang, M.D., MacKay Memorial Hospital Tamsui Branch
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Schmerzen
- Neurologische Manifestationen
- Erkrankungen des Nervensystems
- Postoperative Komplikationen
- Pathologische Prozesse
- Neurobehaviorale Manifestationen
- Wahrnehmungsstörungen
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Schmerzen, postoperativ
- Agnosie
- Anästhesie und Analgesie
- Analgesie
- Analgesie, Patienten kontrolliert
Andere Studien-ID-Nummern
- 21MMHIS203e
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .